🇺🇸

US SEC Filing Intelligence

· daily

Biotech Small-Cap Approvals — July 15, 2026

During the period of July 15, 2026, the FDA approved 4 biosimilar/fallback products, with zero NMEs, zero label expansions, and zero biosimilars (as defined by the stream's mix). All approvals are classified as 'Other' fallback entries, generating 4 neutral signals with no bullish or bearish catalysts. The dominant theme is generic/biosimilar market entries by small-cap sponsors including LAURUS, BELOTECA, APOTEX, and SQUARE PHARMS PLC, targeting established molecules (RILPIVIRINE HYDROCHLORIDE, ILOPROST, MAGNESIUM SULFATE, and an undisclosed drug). The highest-conviction signal is the lack of novel drug approvals, indicating a quiet period for pipeline-driven catalysts. Key risks include limited commercial differentiation and pricing pressure in mature therapeutic categories, with no IRA exposure flags due to the absence of branded drugs.

4 total filings
· daily

Big Pharma Approvals — July 15, 2026

This period's FDA digest covers a single label expansion approval for Eli Lilly's abemaciclib (Verzenio), classified as a 'fallback' type with a modest bullish signal. The approval mix is zero NMEs, zero biosimilars, and zero standard label expansions, making this a low-velocity week for new drug catalysts. The dominant signal is Eli Lilly's continued lifecycle management of its CDK4/6 inhibitor franchise, though the lack of commercial details (peak sales, pricing, exclusivity) limits conviction. Key watch items include potential competitive dynamics from Novartis' Kisqali and Pfizer's Ibrance in the adjuvant breast cancer setting, as well as IRA exposure risk for this small molecule. Investors should view this as a maintenance event rather than a transformative catalyst.

1 total filings
· daily

New Drug Approvals (Original) — July 15, 2026

The July 15, 2026 approval stream delivered four biosimilar/fallback approvals with zero NMEs, zero label expansions, and zero biosimilar designations explicitly flagged, resulting in a neutral signal across all events. The period lacked therapeutic area clustering, as approvals spanned RILPIVIRINE HYDROCHLORIDE (Laurus), ILOPROST (Beloteca), an undisclosed agent from Apotex, and MAGNESIUM SULFATE (Square Pharms PLC) — none with disclosed peak sales, exclusivity, or pricing data. The highest-conviction signal is the absence of any NME or breakthrough therapy approval, indicating a low-catalyst week for innovative biotech investors. Key risk: the lack of commercial detail on all four approvals limits actionable investment conclusions, and the undisclosed Apotex approval introduces opacity risk for competitive dynamics in its target market.

4 total filings
· daily

New Federal Contractors — July 15, 2026

The single contract in this period, a $83.4 million delivery order from the USDA to EPSILON INC (a subsidiary of AMERICAN SYSTEMS CORPORATION), is entirely civilian and carries a neutral signal. The contract provides long-term revenue visibility through 2032 but is firm-fixed-price, transferring cost risk to the contractor. The award under full-and-open competition with a Service Disabled Veteran Owned Small Business preference suggests policy-driven access rather than a pure competitive moat. Key risks include federal budget uncertainty affecting option exercise and execution risk on a fixed-price IT support contract. The highest-conviction signal is the potential $346.5 million total value if all options are exercised, but this remains contingent on USDA budget cycles and performance satisfaction.

1 total filings
· daily

Significant Contract Modifications ($10M+) — July 15, 2026

This digest covers a single $83.4 million civilian contract modification awarded to EPSILON INC, a subsidiary of AMERICAN SYSTEMS CORPORATION, by the Department of Agriculture for DISC IT support services. The contract is entirely civilian, with no defense-related awards in the period. The highest-conviction signal is the long-term revenue visibility through 2032, though the firm-fixed-price structure and reliance on option exercise create execution and budget risk. Key watch items include USDA option announcements and parent company financial disclosures for revenue realization.

1 total filings
· daily

Contract Deobligations Alert — July 15, 2026

This single-record digest covers a $83.4 million civilian deobligation from the USDA to EPSILON INC, a subsidiary of AMERICAN SYSTEMS CORPORATION, for DISC IT support services. The award is entirely civilian, with zero defense exposure, and carries a neutral signal strength of 6/10. The highest-conviction signal is the long-term revenue visibility through 2032, but this is tempered by execution risk from the firm-fixed-price structure and the fact that this is a deobligation alert, not a new award. The key risk is federal budget uncertainty under a potential Continuing Resolution, which could delay option exercise on the $346.5 million ceiling.

1 total filings
· daily

Contract Option Exercises — July 15, 2026

This digest covers a single, large civilian contract option exercise totaling $83.4 million, with zero defense-related activity. The sole award is a 10-year, firm-fixed-price delivery order from the USDA to EPSILON INC, a subsidiary of AMERICAN SYSTEMS CORPORATION, for DISC IT support services. The contract's long duration through 2032 provides high revenue visibility, but the fixed-price structure places execution risk on the contractor. The highest-conviction signal is neutral, as the award is a stable, recurring civilian IT need, but the lack of defense exposure and medium pricing risk temper the bullish case. Key watch items include future option exercises and USDA budget stability under a potential Continuing Resolution.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — July 15, 2026

This single-contract digest covers a $83.4 million civilian IT award from the Department of Agriculture to EPSILON INC, a subsidiary of AMERICAN SYSTEMS CORPORATION, with zero defense-related activity. The dominant theme is long-duration civilian IT support services, with the contract running through 2032 and a potential total value of $346.5 million if all options are exercised. The highest-conviction signal is neutral: the contract provides multi-year revenue visibility for AMERICAN SYSTEMS CORPORATION, but the firm-fixed-price structure places execution risk on the contractor. A key risk is that federal budget uncertainty under a potential Continuing Resolution could delay or cancel option exercises, particularly given the civilian agency context.

1 total filings
· daily

High-Value Federal Grants ($5M+) — July 15, 2026

This digest covers a single high-value civilian grant: an $83.4 million firm-fixed-price delivery order from the USDA to EPSILON INC (a subsidiary of AMERICAN SYSTEMS CORPORATION) for DISC IT support services, with a total potential value of $346.5 million if all options are exercised through 2032. The contract is entirely civilian, with no defense exposure, and carries a neutral signal (strength 6/10) due to the long-term revenue visibility offset by execution risk inherent in the fixed-price structure. The highest-conviction signal is the moderate revenue visibility for EPSILON INC, but the key risk is federal budget uncertainty and the potential for option non-exercise, which could materially reduce the $34.6 million annual run-rate implied by the full contract ceiling. Investors should monitor USDA option exercise announcements and AMERICAN SYSTEMS CORPORATION's financial disclosures for contract contribution details.

1 total filings
· daily

General Federal Contracts — July 15, 2026

This digest covers a single $83.4 million civilian contract awarded to EPSILON INC, a subsidiary of AMERICAN SYSTEMS CORPORATION, by the Department of Agriculture for DISC IT support services. The contract is entirely civilian, with no defense-related awards in the period. The dominant theme is stable, long-term civilian IT services, with the contract running through 2032 and a total potential value of $346.5 million if all options are exercised. The highest-conviction signal is neutral, reflecting a long-term revenue stream offset by firm-fixed-price execution risk and federal budget uncertainty. Key risks include option exercise dependency and potential budget constraints from continuing resolutions.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — July 15, 2026

The four filings for July 15, 2026, reveal a clear and concerning pattern of insider selling across the S&P 500 Technology sector, particularly concentrated in the cybersecurity sub-sector. The most significant signal is the aggressive selling by CrowdStrike's CEO and a Director, totaling over $3.4 million, which, combined with Datadog's CEO selling $10.8 million under a 10b5-1 plan, creates a bearish sentiment for high-growth software names. In contrast, Microsoft's filing is a routine tax withholding event with no strategic signal, highlighting the divergence between a mature mega-cap and its growth peers. The lack of any positive period-over-period comparisons, forward guidance, or capital allocation activity (buybacks/dividends) in these filings amplifies the negative tone. The primary takeaway is a potential loss of management conviction in the cybersecurity and observability sub-sectors, which warrants a defensive posture for investors until upcoming earnings calls provide fundamental context.

3 high priority 1 medium 4 total filings
· daily

Nasdaq 100 Stocks SEC Filings — July 15, 2026

The six filings for the NASDAQ-100 stream reveal a stark divergence between a single, high-quality growth story (ASML) and a cluster of insider selling activity at CoreWeave and Meta. ASML's Q2 2026 results are a standout, with strong revenue and net income, and a raised full-year outlook that signals robust demand for its semiconductor equipment. This positive sentiment is a powerful counterweight to the bearish signals from insider transactions. The most critical development is the concentrated insider selling at CoreWeave, where the Chief Development Officer has sold nearly all of his stake, and the CFO has also liquidated a significant position. This pattern, combined with Meta's COO selling over $1M in stock, creates a portfolio-level theme of management cashing out. The lack of period-over-period data for the insider filings limits trend analysis, but the sheer volume and nature of the sales are actionable red flags. The overall portfolio picture is one of a high-conviction long opportunity in ASML, offset by significant risk signals from insider behavior at other key holdings.

4 high priority 2 medium 6 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — July 15, 2026

The July 15, 2026 batch of 50 filings reveals a dominant theme of passive institutional accumulation, particularly by Bank of Nova Scotia (BNS) and Pzena Investment Management, across diverse sectors including crypto-mining (CleanSpark, TeraWulf), defense tech (Voyager Technologies), and legacy manufacturing (Magna, Hooker Furnishings). Pzena has emerged as a significant, high-conviction holder, establishing or increasing stakes above 8% in six companies (Magna, Globant, Hooker, Amdocs, Corebridge, ScanSource), signaling a value-oriented thesis on these names. The most critical development is Warren Buffett's massive charitable donation of 9 million Berkshire Hathaway B-shares, a planned transfer that reduces his economic stake but maintains voting control. A notable activist development is the cooperation agreement at Repay Holdings, where a 9.38% holder secured a board seat, while Rayonier Advanced Materials is in play with a formal strategic alternatives process drawing interest from AIP. Several micro-cap filings (Vivos, Newton Golf, Elong Power) feature complex capital structures with beneficial ownership blockers, indicating high-risk, structured investments. Overall, the digest points to a market where large passive managers are rotating capital into mid-cap value, while select special situations (M&A, board fights) offer event-driven opportunities.

7 high priority 43 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — July 15, 2026

The 15 filings reveal a mixed picture for S&P 500 Financials. Top asset managers BlackRock and Morgan Stanley posted record results with strong revenue growth and inflows, but Bernstein's Progressive saw deteriorating underwriting margins and Mastercard insiders sold shares. PNC reported record revenue but capital ratios slipped. Berkshire Hathaway's large donation reduced Buffett's economic stake. The sector shows bifurcation between wealth/asset management strength and insurance/credit headwinds, with capital constraints emerging at banks. Insider activity is mostly neutral-to-negative, with notable selling at Mastercard. MUFG's resumption of Morgan Stanley sales plan adds overhang.

8 high priority 7 medium 15 total filings
· daily

S&P 500 Energy Sector SEC Filings — July 15, 2026

The single filing today from Texas Pacific Land Corp (TPL) involves a 10% owner, Horizon Kinetics Asset Management, purchasing 1 share at $408.37. While the transaction is nominal in size (materiality 2/10), the buying action from a significant long-term holder may signal a lack of selling pressure. No other filings were available for the S&P 500 Energy sector today, limiting cross-company comparisons. The purchase occurs against a backdrop of steady energy sector performance, with TPL’s unique royalty-based business model providing exposure to Permian Basin production. The minimal insider activity offers limited actionable insights but warrants monitoring for any follow-up transactions or broader insider buying patterns.

1 high priority 1 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — July 15, 2026

The four filings in the Consumer Staples sector for July 15, 2026, reveal a mixed picture of insider sentiment and capital allocation. The most notable developments are two insider sales events: a significant $1.76M sale by Kroger's EVP and a $1.35M sale by Hershey's 10% owner (the Milton Hershey School Trust), both flagged as negative signals. In contrast, McCormick & Co. shows neutral insider activity with phantom stock awards to top executives, suggesting a focus on long-term retention rather than cash realization. No period-over-period financial trends, forward-looking guidance, or capital allocation changes were reported in these filings, limiting the ability to identify broad sector themes. The primary actionable intelligence centers on the divergence in insider behavior—selling at Kroger and Hershey versus non-cash compensation at McCormick—which may indicate varying levels of management conviction across the subsector. The lack of operational metrics or guidance changes leaves a gap in catalyst calendar construction, but the insider sales warrant close monitoring for potential further deterioration.

4 high priority 4 total filings
· daily

S&P 500 Industrials Sector SEC Filings — July 15, 2026

The two filings in this digest present a stark contrast within the S&P 500 Industrials stream. Deere & Co. executed a routine debt offering to finance its Canadian operations, signaling a neutral capital markets activity with no material impact on its operational outlook. In contrast, Paychex Inc. reported a significant insider transaction where a director exercised and then sold a large block of shares, netting over $21M in proceeds. This insider activity, particularly the outright sale of shares at market price, raises a bearish signal regarding management conviction. The lack of period-over-period comparisons or forward-looking guidance in these filings limits the ability to identify broad sector trends, but the insider action at Paychex warrants immediate attention for investors monitoring executive sentiment in the business services subsector.

1 high priority 1 medium 2 total filings
· daily

US Material Events SEC 8-K Filings — July 15, 2026

The 49 filings reveal a market dominated by significant capital markets activity and corporate restructuring, with a notable wave of debt refinancing totaling over $6 billion from Sunbelt Rentals, SBA Communications, Prestige Consumer Healthcare, and others. M&A activity is highlighted by TriCo Bancshares' acquisition by First Hawaiian in a tax-free stock-for-stock deal valued at 2.095x, and the restructuring of Senti Biosciences and Glucotrack via spin-offs and reverse mergers. Biotech companies are aggressively raising capital: Q32 Bio ($187.6M equity), AEON Biopharma ($13.75M+ warrants), and Fermi Inc. ($431.25M convertible) for advanced projects. However, governance risks are elevated, with High Wire Networks restating three quarters due to a $1.37M error, Regen BioPharma facing going concern and auditor changes, and Lipella Pharma filing for Chapter 11 bankruptcy. Leadership transitions are widespread, including CEO successions at Hanover Insurance and RxSight, and CFO retirements at Celldex. The overall theme is a bifurcated market: strong firms lock in low-cost debt while weaker firms restructure or face liquidity pressures.

49 high priority 49 total filings
· daily

Insider Trading Pulse — July 15, 2026

The July 15, 2026, insider trading digest reveals a market dominated by routine, non-discretionary transactions, with 50 filings analyzed. The most significant cluster is a coordinated, large-scale exercise of stock compensation by seven directors and executives at Mitsubishi UFJ Financial Group (MUFG), totaling over 255,000 shares acquired, signaling strong internal alignment and a bullish view on the Japanese banking giant. A second major theme is a broad-based director compensation award at GDS Holdings, where nine directors were granted ADSs, indicating a focus on long-term retention. In contrast, the only outright bearish signal is a small open-market sale by a director at EuroDry Ltd., while a positive signal comes from a CEO at VIVOS INC making a small open-market purchase. The day's activity is largely devoid of aggressive insider selling, suggesting a general lack of immediate concern among corporate insiders, but also a lack of strong conviction buying outside of scheduled compensation events. The most actionable intelligence stems from the MUFG insider cluster and the VIVOS CEO purchase, which warrant further investigation.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — July 15, 2026

The seven filings from Dow 30 constituents reveal a mixed picture for the second quarter of 2026. Johnson & Johnson delivered solid top-line growth of 6.6% YoY, driven by its Innovative Medicine and MedTech segments, and raised its full-year guidance, signaling confidence. However, GAAP earnings were flat, and currency headwinds and a major drug's patent cliff (STELARA) pose ongoing risks. Nike's annual report shows a company in a prolonged downturn, with flat revenues and a 10% decline from fiscal 2024, alongside significant weakness in Greater China (-11%) and its Converse brand (-31%), though its EBIT margin showed a slight improvement. American Express's delinquency data is a mixed signal: improving net write-off rates are partly due to a one-time sale of bad debt, masking underlying consumer credit trends. The remaining filings are low materiality, covering routine governance updates (Visa), proxy solicitations (Nike), and a minor insider transaction (Microsoft). The overarching theme is a bifurcation between healthcare strength and consumer-facing headwinds, with credit quality requiring close monitoring.

3 high priority 4 medium 7 total filings